Q2 2026 saw 4% revenue growth to $6.68B and net income rise to $785M, driven by higher yield and efficiency gains, despite commodity price headwinds and lower Healthcare Solutions volumes. Free cash flow increased 35% year-over-year, and $1B was returned to shareholders via buybacks.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.